[Clinicomorphological assessment of budesonide efficiency in patients with bronchial asthma].
OBJECTIVE
to study clinicomorphological efficacy of inhalation glucocorticosteroid budesonide (benacort, Pulmomed, Russia) in bronchial asthma.


METHODS
Twenty patients with bronchial asthma were treated with budesonide.


RESULTS
A response to budesonide was manifest to the end of treatment week 1. Budesonide reduced frequency of acute asthma episodes and the need in inhalations of short-acting beta 2-agonists. The peak expiratory velocity (PEV) rose by 12% in three months, variability of PEV lowered by 13%, in 6 months by 21%, in 12 months by 31% compared to pretreatment values. In 12 months hypersecretion and thickness of basal membrane decreased. Three-month treatment also reduced eosinophil and lymphocyte epithelial count and cell density of stromal infiltrate in bronchial mucosa. In 12 months cell density of stromal infiltrate diminished.


CONCLUSIONS
Bronchial asthma treatment with budesonide for 12 months reduces 24 hour rate of acute asthma episodes, the need in the disease exacerbations, improves functional indices of respiration but morphological composition of bronchial mucosa does not normalize completely this showing the necessity of longer budesonide administration.
Budkova
A A
AA
Volkova
L I
LI
Budkov
S R
SR
Bogomiagkov
V S
VS
D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology; D001980:Bronchi / Q000187:drug effects / Q000473:pathology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001999:Bronchoscopy; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D020545:Respiratory Mucosa / Q000187:drug effects / Q000473:pathology; D013147:Spirometry
D001993:Bronchodilator Agents; D019819:Budesonide